Posts by Sandra Ansanay-Alex
Switzerland to India: Navigating Healthcare Market Entry in a Changing Landscape
Switerland Global Enterprise is organising the event Switzerland to India: Navigating Healthcare Market Entry in a Changing Landscape on 27 November 2025 at Aquatis Hotel, Lausanne. India’s healthcare sector is experiencing unprecedented transformation. With a population of 1.4 billion, rising healthcare awareness, and government initiatives driving medical infrastructure development, the Indian market presents extraordinary…
Read MoreHemostOD Secures CHF 4.3M Seed Extension
HemostOD, a Swiss Health Valley company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, announces the successful closing of a CHF 4.3 million Seed-extension financing. The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors. Proceeds from this financing…
Read MoreAI-Powered Precision Oncology: NAIPO Launches in Switzerland
A new national initiative, NAIPO (National AI Initiative for Precision Oncology), is set to transform cancer care in Switzerland by leveraging artificial intelligence (AI) to enable truly personalized treatments. Led by the EPFL AI Center and ETH AI Center, NAIPO will run over four years and bring together a large, interdisciplinary team from Swiss…
Read MoreUndae Science and StudentsPool Supported by FIT
Two Swiss Health Valley startups supported by Fondation pour l’Innovation Technologique (FIT) are tackling some of healthcare’s most pressing challenges: diagnosing sleep disorders and addressing critical staff shortages. Undae Science: Making Sleep Monitoring Easier and More Accurate Sleep disorders affect one in three people in Switzerland and cost the economy more than CHF 10…
Read MoreGimv announces a CHF 28 Million Investment in Spineart
The European investment company listed on Euronext Brussels is thereby becoming a major shareholder. These funds will be used to strengthen Spineart’s organisation and commercial processes, pursue its geographical expansion in certain markets such as the United States, and continue the development of innovative products. Spineart is a rapidly growing Geneva-based medical device company.…
Read MoreBioArk & New Mexico Venture Studios Partner to Boost Life Sciences Projects
BioArk & New Mexico Venture Studios have established a strategic partnership to support startups in life sciences, medtech, and deep tech. This alliance facilitates access to infrastructure, expertise, and markets between US and European markets, accelerating international growth and collaboration. Facilitating startup expansion and collaboration The partnership provides startup exchange programs, shared lab and…
Read MoreBioLNP Innovation and OneCell Protein, recipients of the EPFL Startup Launchpad Ignition Grant
Two EPFL-based startups: BioLNP Innovation and OneCell Protein, have become the latest recipients of the EPFL Startup Launchpad Ignition grant. The startups were each awarded a CHF30,000 grant to continue developing their technology. BioLNP Innovation Viruses (including Respiratory Syncytial Virus or Hepatitis B) are a major public health concern. While scientists have developed treatments…
Read MoreARCHIMED acquires cell line development pioneer ExcellGene
Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics. Monthey, Switzerland-based ExcellGene, was created…
Read MoreBioscibex Receives CHF 150,000 from Venture Kick
EPFL spin-off Bioscibex, a biotechnology start-up specialising in bioproduction equipment, has secured CHF 150,000 in funding from Venture Kick. This fundraising will accelerate the market launch of Swingo, its first single-use bioreactor, designed to simplify and automate cell culture and thus make biological therapies more accessible. Biologics have transformed the treatment of cancer, autoimmune…
Read MoreMultiwave Technologies Secures CHF 3.6M and Expand Operations in the US
Geneva-based Multiwave Technologies AG has raised CHF 3.6 million (USD 4.5 million) in fresh funding to accelerate the development and regulatory approval of its portable MRI device, MGNTQ™, and to expand its global operations with a new assembly plant in Lowell, Massachusetts. The investment, completed across 2024 and 2025, comes from a group of…
Read More